Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate

Sophie Vanhaesebrouck*, Veerle Cossey, Katrien Cosaert, Karel Allegaert, Gunnar Naulaers

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Purpose. Brimonidine is a third-generation selective alpha-2 adrenergic agonist that lowers intraocular pressure by decreasing aqueous humor production and increasing uveoscleral flow. Its safety profile for children <2 years of age remains unknown. Methods. We describe a case of ingestion of a single drop of brimonidine 0.2% in a newborn, resulting in sedation, cardiorespiratory depression, and hyperglycemia within minutes. Conclusions. This report adds to the existing evidence that brimonidine can have serious adverse side effects and should therefore be used with extreme caution in infants <2 years of age. Additionally, safety procedures like double-checking should also include vitamins or oral supplements to improve medication safety in the neonatal intensive care unit.

Original languageEnglish
Pages (from-to)694-695
Number of pages2
JournalEuropean Journal of Ophthalmology
Volume19
Issue number4
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate'. Together they form a unique fingerprint.

Cite this